Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Cytel, officially known as Cytel Inc., is a leading provider of advanced statistical software and services, headquartered in the United States. Founded in 1981, the company has established a strong presence in the biostatistics and clinical trial sectors, with major operational regions across North America, Europe, and Asia.
Cytel is renowned for its innovative solutions in clinical development, particularly its software products like East and StatXact, which streamline the design and analysis of clinical trials. These offerings are distinguished by their robust statistical methodologies and user-friendly interfaces, catering to the needs of pharmaceutical and biotechnology companies.
With a commitment to enhancing the efficiency of clinical research, Cytel has achieved significant milestones, including partnerships with leading global organisations. Its reputation as a trusted partner in the industry underscores its market position and dedication to advancing healthcare through data-driven insights.
-12 vs industry average
Cytel’s score of 20 is lower than 49% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Device Manufacturing has below-average carbon intensity
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Scope 3 accounts for ••• of total emissions.
In 2023, Cytel Inc., headquartered in the United States, reported total carbon emissions of approximately 7,126,850 kg CO2e. This figure includes 3,570 kg CO2e from Scope 1 emissions, 47,270 kg CO2e from Scope 2 emissions (market-based), and 7,121,010 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions are primarily driven by purchased goods and services (4,863,000 kg CO2e), business travel (896,300 kg CO2e), and employee commuting (1,072,700 kg CO2e).
Cytel has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline. Additionally, the company targets a 51.6% reduction in Scope 3 emissions per million USD value added within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C.
Cytel's commitment to sustainability reflects its proactive approach to addressing climate change and reducing its carbon footprint across all scopes of emissions.
2030
42% reduction in Scope 1
Cytel Inc. commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by FY2030 from a FY2022 base year. Cytel Inc. also commits to reduce…
2030
42% reduction in Scope 2
Cytel Inc. commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by FY2030 from a FY2022 base year. Cytel Inc. also commits to reduce…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Cytel’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more